Try our beta test site
6 studies found for:    Polatuzumab Vedotin
Show Display Options
Rank Status Study
1 Active, not recruiting A Study of Polatuzumab Vedotin in Combination With Rituximab or Obinutuzumab, Cyclophosphamide, Doxorubicin, and Prednisone in Participants With B-Cell Non-Hodgkin's Lymphoma
Condition: Lymphoma, Non Hodgkin
Interventions: Drug: Cyclophosphamide;   Drug: Doxorubicin;   Drug: Obinutuzumab;   Drug: Polatuzumab Vedotin;   Drug: Prednisolone;   Drug: Prednisone;   Drug: Rituximab
2 Recruiting A Study of Obinutuzumab, Polatuzumab Vedotin, and Atezolizumab in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Condition: Lymphoma
Interventions: Drug: Atezolizumab [TECENTRIQ];   Drug: Obinutuzumab;   Drug: Polatuzumab Vedotin
3 Recruiting A Study of Obinutuzumab, Polatuzumab Vedotin, and Lenalidomide in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Condition: Relapsed or Refractory Follicular Lymphoma, Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Interventions: Drug: Lenalidomide;   Drug: Obinutuzumab;   Drug: Polatuzumab Vedotin
4 Active, not recruiting A Study of Pinatuzumab Vedotin (DCDT2980S) Combined With Rituximab or Polatuzumab Vedotin (DCDS4501A) Combined With Rituximab or Obinutuzumab in Participants With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Condition: Lymphoma, Follicular, Diffuse Large B-Cell Lymphoma
Interventions: Drug: Obinutuzumab;   Drug: Pinatuzumab Vedotin;   Drug: Polatuzumab Vedotin;   Drug: Rituximab
5 Recruiting A Study of Obinutuzumab, Rituximab, Polatuzumab Vedotin, and Venetoclax in Relapsed or Refractory Follicular Lymphoma (FL) or Diffuse Large B-Cell Lymphoma (DLBCL)
Condition: Non-Hodgkin's Lymphoma
Interventions: Drug: Obinutuzumab;   Drug: Rituximab;   Drug: Polatuzumab Vedotin;   Drug: Venetoclax
6 Recruiting A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Condition: Lymphoma
Interventions: Drug: Bendamustine;   Drug: Obinutuzumab;   Drug: Polatuzumab vedotin;   Drug: Rituximab

Study has passed its completion date and status has not been verified in more than two years.